Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059419 | 0.88 | SMN1; SMN2 (0.42) | TACR1 | |
| SCHEMBL3299439 | 0.86 | TACR1 (0.49) | TACR1TACR3CCR2 | |
| SCHEMBL7744085 | 0.78 | HDAC8 (0.41) | TACR1GPR139KMT2ATACR3 | |
| SCHEMBL18620721 | 0.75 | HSD17B10 (0.66) | TACR1ATML3MBTL1GPR139MEN1 | |
| SCHEMBL11512864 | 0.74 | MAPT (0.49) | TACR1 | |
| SCHEMBL6811096 | 0.74 | ALDH1A1 (0.46) | GPR139MEN1KMT2A | |
| SCHEMBL3300429 | 0.72 | TACR1 (0.52) | TACR1CCR2 | |
| SCHEMBL6814704 | 0.72 | TLR8 (0.49) | MEN1KMT2A | |
| SCHEMBL14210386 | 0.70 | CASR (0.53) | TACR1ATML3MBTL1MEN1KMT2A | |
| SCHEMBL12402687 | 0.70 | CASR (0.53) | TACR1ATML3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | claimed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | claimed |
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | disclosed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | TST, TPX2, TPMT | TACR1 2235/4885ATM 2855/4885L3MBTL1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.